Yingqiu Yvette Liu PAREXEL International

Slides:



Advertisements
Similar presentations
Matthew M. Riggs, Ph.D. metrum research group LLC
Advertisements

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Converting Pharmacokinetic Data to the PP and PC Domains
Clinical Pharmacokinetics
Pharmacokinetics (PK) ®The study of the disposition of a drug ®The disposition of a drug includes the processes of ADME -  Absorption  Distribution.
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
Verify or refute the use of Non Linear Mixed Effect Model for Interferon effect on HCV Hila David Shimrit Vashdi Project Advisors: Prof. Avidan Neumann.
B10analytics b e y o n d s i g n i f i c a n c e Your Perfect Analysis Partner
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Pharmacokinetics (PK): What the body does to the drug? Most drugs: Enter the body by crossing barriers Distributed by the blood to the site of action Biotransform.
Modeling Systems and Processes Anthony McGoron, PhD Associate Professor Department of Biomedical Engineering Florida International University.
Fundamentals of Drug Action
Concepts and Applications of Pharmacokinetics
PHARMACOKINETIC MODELS
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
Modeling and Simualtion: challenges for the clinical programmer and for the group leader Vincent Buchheit PHUSE 2010.
PHARMACEUTICS- IV (PHT 414 ) Dr. Mohammad Khalid Anwer SALMAN BIN ABDUL AZIZ UNIVERSITY COLLEGE OF PHARMACY L111/16/2016.
INTRODUCTION CLINICAL PHARMACOKINETICS
Introduction of Biopharmaceutics and Pharmacokinetics
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Study Aids Anki Flash cards – Content that you need to know for the tests. MS Excel sheet with Calculations.
PHT 415 BASIC PHARMACOKINETICS
Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,
415 PHT Plasma Level – Time Curve
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
How Good is Your SDTM Data? Perspectives from JumpStart Mary Doi, M.D., M.S. Office of Computational Science Office of Translational Sciences Center for.
Working Efficiently with Large SAS® Datasets Vishal Jain Senior Programmer.
Definitions and Concepts
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Introduction to Biopharmaceutics and Pharmacokinetics
MS WinNonLin Project 9/28/15: PK Modeling I project due today.
Drug Response Relationships
Physiology for Engineers
Challenges and Strategies in Pharmacometric Programming
Introduction of Biopharmaceutics & Pharmacokinetics
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
The main branches of pharmacology
Understanding the Basics of Pharmacology
ADME/Tox PredictionTox Prediction. The characterization of Absorption, Distribution, Metabolism, and Excretion (also known as ADME) and Toxicity are essential.
Pharmacokinetics.
Hanneke van der Lee, MD, PhD
Biopharmaceutics Dr Mohammad Issa Saleh.
Simone M. Shurland, Ph.D., Division of Anti-Infective Products
Orientation to Pharmacology
Clinical Pharmacokinetics
Food Chemicals Toxicity
INTRODUCTION to Pharmacology
Fabienne NOEL CDISC – 2013, December 18th
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Insight into the Pharmaceutical Industry
MTN-037 Protocol Overview
Visualizing Subject Level Data in Clinical Trial Data
Introduction to Pharmacology
My typical day as a scientist in pre-clinical at AZ/MedI
Chapter 1 Introduction of Pharmacology [,fɑ:mə'kɔlədʒi] 药理学
Therapeutic Drug Monitoring chapter 1 part 1
Introduction to Pharmacology
Chapter 1 Introduction of Pharmacology [,fɑ:mə'kɔlədʒi] 药理学
Selvadurai Muralidharan, Kalaimani Jaya Raja Kumar
Introduction to Pharmacogenetics
Introduction to Pharmacology
ADME Study PK SDTM/ADAM And Graph
Presentation transcript:

A Practical and Efficient Method of Calculating Actual Time Since Last Dose Data in PK Analysis Yingqiu Yvette Liu PAREXEL International PhUSE Connect 2018, Raleigh, NC June 3rd - 6th, 2018

1. Introduction Figure 1. source: Peter Schaefer, Overview of Handling PK Data in CDISC Standard

1. Introduction Pharmacokinetics (PK): is what the body does to the drug, it characterizes the time course of concentrations of the drug and/or the drug metabolite after drug administration in order to obtain information on drug disposition in the body. 4 phases of PK process inside the body- ADME: Absorption, Distribution, Metabolism, Excretion. Pharmacodynamics (PD): is what the drug does to the body, it studies the body’s pharmacological response to a drug (measured in terms of AEs & Efficacy). PKPD: studies the dose-effect relationship.

2. EX & PC datasets Figure 2. EX dataset

2. ADPC dataset Figure 4. ADPC dataset

3. PKNCA: Non-Compartmental PK Analysis Dataset 3.1 Calculate ATSLD (Actual Time Since Last Dose) Step 1: Create a common variable DTM in both ADPC and ADEX datasets.   data ex1(keep=usubjid exdtm dtm extrt exdose); set adex; exdtm=adtm; dtm = adtm; format exdtm dtm is8601dt.; run; data pk1; set adpc; pkdtm=adtm; format pkdtm dtm is8601dt.;

3.1 Calculate ATSLD (Actual Time Since Last Dose) Step 2: Set PK and EX together into PKEX. Using numeric flag SRCFN to differentiate data source whether data comes from EX of PK.   data pkex1; set ex(in=a) pk1(in=b) ; if a then srcfn = 1; if b then srcfn = 0; run; Step 3: Sort PKEX by USUBJID, DTM, SRCFN. proc sort data = pkex1; by usubjid dtm srcfn;

3.1 Calculate ATSLD (Actual Time Since Last Dose) EX1 (step1) PK1 (step 1) PKEX1 (step 3)

3.1 Calculate ATSLD (Actual Time Since Last Dose) Step 4: Using LAG( ) function and RETAIN statement to populate LDOSEDTM for each post-dose PK record.   data pkex2; set pkex1; by usubjid dtm; format lagexdtm ldosedtm is8601dt. ; retain ldosedtm; lagexdtm = lag(exdtm); if first.usubjid then do; lagexdtm = .; ldosedtm = .; end; if lagexdtm ne . then ldosedtm = lagexdtm; run;

3.1 Calculate ATSLD (Actual Time Since Last Dose) PKEX2 (step 4)

3.1 Calculate ATSLD (Actual Time Since Last Dose) Step 5: Only keep PK records.   data pkex3; set pkex2; by usubjid dtm; where srcfn = 0; run; Step 6: Calculate ATSLD for each post-dose PK record, set ATSLD = 0 for pre-dose record. data pkex4; set pkex3; if n(pkdtm,ldosedtm) = 2 then atsld= (pkdtm - ldosedtm)/3600; if index(upcase(TPT), “PRE-DOSE”) > 0 then ATSLD = 0;

3.1 Calculate ATSLD (Actual Time Since Last Dose) PKEX4 (step 6)

3.2 Calculate ATSFD (Actual Time Since First Dose) Step 1: keep only first dose record for each subject in EX dataset.   data ex2(keep=usubjid fdosedtm); set ex1; by usubjid dtm; if first.usubjid; fdosedtm = exdtm; format fdosedtm is8601dt.; run; Step 2: merge EX2 with PKEX4 by USUBJID, now each PK record has FDOSEDTM. data pkex5; merge pkex4(in=a) ex2(in=b); by usubjid; if a;

3.2 Calculate ATSFD (Actual Time Since First Dose) Step 3: calculating ATSFD, set ATSFD = 0 for pre-dose record.   data pkex6; set pkex5; if n(pkdtm,fdosedtm) = 2 then atsfd = (pkdtm - fldosedtm) / 3600; If first.usubjid & index(upcase(TPT), “PRE-DOSE”) > 0 then ATSFD = 0; run;

3.2 Calculate ATSFD (Actual Time Since First Dose) PKEX6 (step 3)

3.3 ATSFD vs. ATSLD In general, ATSFD should only be set to 0 for the pre-dose associated with the very first dose of the drug associated with the analyte (i.e. parent drug or its metabolite) of interest, across all periods. ATSFD should also include the time spent during the washout between periods.   NTSFD, however, should be calculated for each period, with the reference day corresponding to the day that the first dose of the drug of interest was given. So basically, NTSFD is used to keep track of the time since the first dose of the drug given within a period (note, this isn’t always Day 1). While ATSFD is keeping track of the real time since the subject took the very first dose of the drug of interest (which includes the washout periods).

Thanks. Questions. Yingqiu Yvette Liu, PAREXL Internaltional yvette Thanks! Questions? Yingqiu Yvette Liu, PAREXL Internaltional yvette.liu@parexel.com